Baker Bros. Advisors Q2 2026 Investment Activity: Significant Shifts in Biotech Portfolio
Baker Bros. Advisors' portfolio saw notable changes this quarter with substantial reductions in positions like CERS and SMMT, alongside significant increases in Revolution Medicines (RVMD) and Insmed Incorporated (INSM). The firm maintains a heavy concentration in the Healthcare sector.
According to data available on InsightEdge, Baker Bros. Advisors' portfolio experienced significant changes during the second quarter of 2026, ending as of June 30th.
The investment firm was notably active in divesting certain stocks this period. The most substantial reduction occurred in Cerus Corporation (CERS), where the position decreased by 36% or a total of -3,612,914 shares.
Another significant exit was from Summit Therapeutics Inc. (SMMT), which saw its stake reduced by 9.9% (-3,604,715 shares).
Furthermore, Edgewise Therapeutics, Inc. (EWTX) experienced a sharp decline of 43.7% (-2,874,221 shares) in its holding.
Baker Bros. Advisors also sold smaller positions during Q2 2026, including Cerus, Edgewise Therapeutics, and others.
Conversely, the firm demonstrated strong buying activity in several quarters. Notably, they significantly increased their position in Revolution Medicines (RVMD) by 19.76%, acquiring an additional 1,888,000 shares.
They also substantially boosted Insmed Incorporated (INSM)'s allocation by 18.53% during the quarter, adding another 1,375,000 shares to their existing stake.
Beyond these major additions, Baker Bros. Advisors purchased smaller stakes in other companies like Celldex Therapeutics (CLDX), Arcus Biosciences (RCUS), and others.
Overall, Baker Bros. Advisors' portfolio allocation remained heavily concentrated in the Healthcare sector throughout this period.